| ORGN | Monday, September 8, 2003 | ||
8:30 AM-11:55 AM Sheraton New York -- Imperial Ballroom A,Oral | |||
Role of Organic Synthesis in Early Clinical Drug Development | |||
| Organizer, Presiding: | Ahmed F. Abdel-Magid | ||
| 8:30 AM | Introductory Remarks | ||
| 8:35 AM | 210 | A commercially viable route and process to HIV PI GW640385X John Roberts | |
| 9:15 AM | 211 | Recent advances in chemical process research Cynthia A. Maryanoff | |
| 9:55 AM | 212 | Asymmetric synthesis of the vasopeptidase inhibitor BMS-189921 David R. Kronenthal | |
| 10:35 AM | 213 | Cross-coupling methods for the synthesis of an imidazole-thienopyridine: Synthesis of [2-(3-methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine John A Ragan, Jeffery W. Raggon, Paul D. Hill, Brian P. Jones, Ruth E. McDermott, M. J. Munchhof, M. M. Marx, J. C. Casavant, Beth A. Cooper, Jonathan L. Doty, Yong Lu | |
| 11:15 AM | 214 | Studies in the design and development of practical syntheses Edward J. J. Grabowski | |
Symposium Grid -- Division of Organic Chemistry -- Session Listing
The 226th ACS National Meeting, New York, NY, September 7-11, 2003